Il nostro standard di qualità: qualità lotto dopo lotto

Avextra è sinonimo di farmaci a base di cannabis di alta qualità. La nostra chiave del successo: la coltivazione in Portogallo e la combinazione di tradizione e alta tecnologia. Per saperne di più, guardate il video con il nostro CMO David Reckeweg-Lecompte.

Podcasts

Neil Smith è ospite da Planted con Sara Payan.

Sara Payan parla con Neil Smith, COO di Avextra, della situazione della cannabis in Europa e dei nuovi sviluppi della ricerca. Qui trovi l’intervista in inglese.

Comunicati stampa

Qui trovate gli ultimi comunicati stampa di Avextra.

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance

Bensheim, Germany, December 3rd 2025 — How can therapy with Cannabis-based medicines (CbM) be designed to be not only therapeutically proven, but also patient-friendly and safe…

Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative

Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative

Arruolato il primo paziente nello studio randomizzato, controllato con placebo Bensheim, 24. ottobre 2025 – Le malattie neurodegenerative rappresentano una delle più grandi sfide del nostro tempo. Solo in Germania vivono oggi...

First Patient Included Marks Major Milestone in EU-Funded Clinical Trial

First Patient Included Marks Major Milestone in EU-Funded Clinical Trial

Bensheim, Germany, August 11, 2025 – PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin…

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Bensheim, Germany, 13th June 2025 — New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines…

Veteran Banker Joins Avextra’s Supervisory Board

Veteran Banker Joins Avextra’s Supervisory Board

Bensheim, Germany, April 3, 2025 – Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board,…

Avextra Showcases Study Findings on World Sleep Day 2025

Avextra Showcases Study Findings on World Sleep Day 2025

Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association…

Avextra Unveils Promising Study Results at Major Pain Congress

Avextra Unveils Promising Study Results at Major Pain Congress

Bensheim, Germany – 13 March 2025 – At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra…

Avextra expanding its product portfolio of cannabis-based medicines

Avextra expanding its product portfolio of cannabis-based medicines

Bensheim, Germany, 6 March 2025 — Avextra is broadening its product portfolio with a 25/25 cannabis extract and is presenting initial study results during the German Pain and Palliative Care Days…

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance

Bensheim, Germany, December 3rd 2025 — How can therapy with Cannabis-based medicines (CbM) be designed to be not only therapeutically proven, but also patient-friendly and safe…

Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative

Avextra supporta in Italia uno studio clinico di fase II sulla cannabis terapeutica nelle malattie neurodegenerative

Arruolato il primo paziente nello studio randomizzato, controllato con placebo Bensheim, 24. ottobre 2025 – Le malattie neurodegenerative rappresentano una delle più grandi sfide del nostro tempo. Solo in Germania vivono oggi...

First Patient Included Marks Major Milestone in EU-Funded Clinical Trial

First Patient Included Marks Major Milestone in EU-Funded Clinical Trial

Bensheim, Germany, August 11, 2025 – PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin…

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients

Bensheim, Germany, 13th June 2025 — New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines…

Veteran Banker Joins Avextra’s Supervisory Board

Veteran Banker Joins Avextra’s Supervisory Board

Bensheim, Germany, April 3, 2025 – Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board,…

Avextra Showcases Study Findings on World Sleep Day 2025

Avextra Showcases Study Findings on World Sleep Day 2025

Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the German Pain and Palliative Care Days, organised by the German Pain Association…

Avextra Unveils Promising Study Results at Major Pain Congress

Avextra Unveils Promising Study Results at Major Pain Congress

Bensheim, Germany – 13 March 2025 – At its annual congress in Frankfurt, Germany, this week, researchers from the DGS will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra…

Avextra expanding its product portfolio of cannabis-based medicines

Avextra expanding its product portfolio of cannabis-based medicines

Bensheim, Germany, 6 March 2025 — Avextra is broadening its product portfolio with a 25/25 cannabis extract and is presenting initial study results during the German Pain and Palliative Care Days…

UFFICIO STaMPa

Lisa Schwede

Tel.: +49 30 408174037

E-Mail: press@avextra.com

IT